ClinicalTrials.gg
CompletedNCT05096221EMBARKUpdated Jul 8, 2025Results posted

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

A Phase 3 interventional study of delandistrogene moxeparvovec and placebo in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 42 sites in 9 countries. Open to male participants aged 4 Years to 7 Years. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by Sarepta Therapeutics, Inc. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
4 Years to 7 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..

Enrollment
6th of 25
126 · median 24
Started
2021
the only one that year
Phase 3
7 of 27
1 open now
Registered
20th of 27
by date

Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 6th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 3, and was the 20th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 7 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., or all of them as a file.
02

Study summary

The study will evaluate the safety and efficacy of gene transfer therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study. The participants who are randomized to the placebo arm will have an opportunity for treatment with gene transfer therapy at the beginning of the second year.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Muscular Dystrophies
  • Duchenne Muscular Dystrophy
  • DMD
  • North Star Ambulatory Assessment (NSAA)
  • Ambulatory
  • Pediatric
  • Gene-Delivery
04

Who can participate

Ages eligible
4 Years to 7 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is ambulatory and from 4 to under 8 years of age at time of randomization.
  • Definitive diagnosis of DMD based on documented clinical findings and prior genetic testing.
  • Ability to cooperate with motor assessment testing.
  • Stable daily dose of oral for at least 12 weeks prior to Screening, and the dose is expected to remain constant throughout the study (except for modifications to accommodate changes in weight).
  • rAAVrh74 antibody titers are not elevated as per protocol-specified requirements.
  • A pathogenic frameshift mutation or premature stop codon contained between exons 18 and 79 (inclusive), with the exception of mutation fully contained within exon 45.

Exclusion criteria

Exclusion Criteria:

  • Exposure to gene therapy, medication, or any treatment designed to increase dystrophin expression within protocol specified time limits.
  • Abnormality in protocol-specified diagnostic evaluations or laboratory tests.
  • Presence of any other illness, medical condition, or requirement for chronic drug treatment that in the opinion of the Investigator creates unnecessary risk for gene transfer.

Other inclusion or exclusion criteria could apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Delandistrogene Moxeparvovec followed by Placebo

    Participants will receive single intravenous (IV) infusion of delandistrogene moxeparvovec on Day 1. Then, participants will receive a single IV infusion of matching placebo at Year 2.

    Genetic: delandistrogene moxeparvovec · Genetic: placebo

  • Placebo comparator
    Placebo followed by Delandistrogene Moxeparvovec

    Participants will receive matching placebo IV infusion on Day 1. Then, participants will have the opportunity to receive a single IV infusion of delandistrogene moxeparvovec at Year 2.

    Genetic: delandistrogene moxeparvovec · Genetic: placebo

Interventions

  • Geneticdelandistrogene moxeparvovec

    Single IV infusion of delandistrogene moxeparvovec.

    Also known as: SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS

  • Geneticplacebo

    Single IV infusion of matching placebo.

06

What researchers measure

Primary outcomes

  1. Part 1: Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 52

    The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). The response vector consists of the change from baseline in NSAA total score at the post-baseline visit. The model includes the covariates of treatment group, visit, treatment group by visit interaction, age group, baseline NSAA total score, and baseline NSAA total score by visit interaction. All covariates are fixed effects in this analysis. An increase in score indicates an improvement in motor function.

    Time frame: Baseline, Week 52 (Part 1)

Secondary outcomes

  1. Part 1: Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12 as Measured by Western Blot Adjusted by Muscle Content

    Quantity of delandistrogene moxeparvovec dystrophin protein levels (in muscle biopsy samples) were determined by Western blot at Part 1, Week 12. For this endpoint, 2 blocks of tissues were analyzed by Western blot, each with 2 technical replicates to determine the delandistrogene moxeparvovec dystrophin protein level (percent control). The block average value from 2 technical replicates was computed. The overall average was calculated as the mean of the block average values. The overall average values were used for the analysis. Dystrophin protein was measured and then adjusted based on the percentage of muscle content in the biopsy sample. An increase in protein expression indicates production of the delandistrogene moxeparvovec dystrophin protein.

    Time frame: Week 12

  2. Part 1: Change From Baseline in Time to Rise From the Floor at Week 52

    The time to rise from the floor test quantifies the time required for the participant to stand in an upright position with arms by sides, starting from the supine position with arms by sides. Data are presented for the change from baseline to Week 52 in the time taken (in seconds) to rise from the floor.

    Time frame: Baseline, Week 52 (Part 1)

  3. Part 1: Change From Baseline in Time to Complete 10 Meter Walk/Run (10MWR) at Week 52

    The timed 10MWR quantifies the time required for the participant to run or walk 10 meters (on a straight walkway) from a standing position. Data are presented for change from baseline to Week 52 in the time (in seconds) taken to complete the 10MWR.

    Time frame: Baseline, Week 52 (Part 1)

  4. Part 1: Change From Baseline in Time to Complete 100 Meter Walk/Run (100MWR) at Week 52

    The timed 100MWR quantifies the time required for the participant to run or walk 100 meters (on a straight walkway) from a standing position. Data are presented for change from baseline to Week 52 in the time (in seconds) taken to complete the 100MWR.

    Time frame: Baseline, Week 52 (Part 1)

  5. Part 1: Change From Baseline in the Timed Stair Ascend 4 Steps Test at Week 52

    The timed stair ascend 4 steps test quantifies the time required for the participant to ascend 4 standard steps (each step was 6 inches in height). Data presented is the change from baseline to Week 52 in the time (in seconds) to ascend 4 steps.

    Time frame: Baseline, Week 52 (Part 1)

  6. Part 1: Change From Baseline in Stride Velocity 95th Centile (SV95C) at Week 52

    Each participant was provided with wearable devices to collect data on stride velocity. Participants wore a device on each ankle. SV95C data was derived based on stride velocity. Data are presented for change from baseline to Week 52 in SV95C.

    Time frame: Baseline, Week 52 (Part 1)

  7. Part 1: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Score in Mobility to Week 52

    PROMIS is a family of instruments developed and validated to assess health-related quality of life, including mobility. Mobility function scores ranged from 1 (worst mobility function) to 5 (best mobility function), where higher scores indicate a better clinical outcome.

    Time frame: Baseline, Week 52 (Part 1)

  8. Part 1: Change From Baseline in PROMIS Score in Upper Extremity Function to Week 52

    PROMIS is a family of instruments developed and validated to assess health-related quality of life, including upper extremity function. Upper extremity function scores ranged from 1 (not able to do so \[worst upper extremity function\]) to 5 (no trouble \[best upper extremity function\]), where higher scores indicate a better clinical outcome.

    Time frame: Baseline, Week 52 (Part 1)

  9. Part 1: Number of Skills Gained or Improved at Week 52 as Measured by the NSAA

    The NSAA is a clinician-administered scale that rates performance on various functional activities. As measured by the NSAA, data was collected for the number of skills gained (the average item score was 0 at Baseline and \> 0 at Part 1 Week 52) or improved (the average item score at Baseline was \> 0 but less than the average item score at Part 1 Week 52). As pre-specified, data are presented for the combined number of skills gained or improved at Week 52.

    Time frame: Week 52 (Part 1)

  10. Parts 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    TEAEs were defined as an adverse event (AE) that emerged during treatment, having been absent pre-treatment, or worsened relative to the pretreatment state. SAEs were defined as any adverse event that resulted in death, was life threatening, required or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or was an important medical event. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to 104 weeks

  11. Parts 1 and 2: Number of Participants With Adverse Events of Special Interest (AESI)

    AESIs were defined as adverse events (AEs) of special interest, based on pre-specified criteria and pertain to categories labeled hepatotoxicity, immune-mediated myositis, thrombotic microangiopathy (TMA), hypersensitivity, thrombocytopenia, rhabdomyolysis, and troponin I elevations. The data represent the number of participants who experienced an event within the specified AESI category as observed by the principal investigator (PI), after adjudication. Per prespecified analysis, AESI data were only collected based on the specified AESI categories. A Summary of all SAEs and nonserious AEs ("Other"), regardless of causality and regardless of the AESI category, is located in the "Reported Adverse Events" section.

    Time frame: Up to 104 weeks

07

Results

Posted Dec 10, 2024

Participant flow

Part 1
Participant flow — Part 1
MilestoneDelandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene Moxeparvovec
Started6362
Received at least 1 dose of study drug in part 16362
Completed6362
Not completed00
Part 2
Participant flow — Part 2
MilestoneDelandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene Moxeparvovec
Started6360
Received at least 1 dose of study drug in part 26260
Completed6359
Not completed01
Withdrew: Physician decision01

Outcome measures

PrimaryPart 1: Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 52

The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). The response vector consists of the change from baseline in NSAA total score at the post-baseline visit. The model includes the covariates of treatment group, visit, treatment group by visit interaction, age group, baseline NSAA total score, and baseline NSAA total score by visit interaction. All covariates are fixed effects in this analysis. An increase in score indicates an improvement in motor function.

Time frame:
Baseline, Week 52 (Part 1)
Reported as:
Least squares mean · scores on a scale
Part 1: Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 52
scores on a scaleDelandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene Moxeparvovec
Part 1: Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 522.57 ± 0.391.92 ± 0.39
Statistical analysis
  • Delandistrogene Moxeparvovec Followed by Placebo vs Placebo Followed by Delandistrogene Moxeparvovec · Mixed model of repeated measures · p = 0.2441 · Least squares mean change difference: 0.65 · 95% CI -0.45 to 1.74
SecondaryPart 1: Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12 as Measured by Western Blot Adjusted by Muscle Content

Quantity of delandistrogene moxeparvovec dystrophin protein levels (in muscle biopsy samples) were determined by Western blot at Part 1, Week 12. For this endpoint, 2 blocks of tissues were analyzed by Western blot, each with 2 technical replicates to determine the delandistrogene moxeparvovec dystrophin protein level (percent control). The block average value from 2 technical replicates was computed. The overall average was calculated as the mean of the block average values. The overall average values were used for the analysis. Dystrophin protein was measured and then adjusted based on the percentage of muscle content in the biopsy sample. An increase in protein expression indicates production of the delandistrogene moxeparvovec dystrophin protein.

Time frame:
Week 12
Reported as:
Mean · Percent control
Part 1: Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12 as Measured by Western Blot Adjusted by Muscle Content
Percent controlDelandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene Moxeparvovec
Part 1: Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression at Week 12 as Measured by Western Blot Adjusted by Muscle Content34.29 ± 41.040.00 ± 0.00
Statistical analysis
  • Delandistrogene Moxeparvovec Followed by Placebo vs Placebo Followed by Delandistrogene Moxeparvovec · Re-randomization test · p = < 0.0001
SecondaryPart 1: Change From Baseline in Time to Rise From the Floor at Week 52

The time to rise from the floor test quantifies the time required for the participant to stand in an upright position with arms by sides, starting from the supine position with arms by sides. Data are presented for the change from baseline to Week 52 in the time taken (in seconds) to rise from the floor.

Time frame:
Baseline, Week 52 (Part 1)
Reported as:
Least squares mean · Seconds
Part 1: Change From Baseline in Time to Rise From the Floor at Week 52
SecondsDelandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene Moxeparvovec
Part 1: Change From Baseline in Time to Rise From the Floor at Week 52-0.27 ± 0.150.37 ± 0.15
Statistical analysis
  • Delandistrogene Moxeparvovec Followed by Placebo vs Placebo Followed by Delandistrogene Moxeparvovec · Mixed model of repeated measures · p = 0.0025 · Least squares mean change difference: -0.64 · 95% CI -1.06 to -0.23
SecondaryPart 1: Change From Baseline in Time to Complete 10 Meter Walk/Run (10MWR) at Week 52

The timed 10MWR quantifies the time required for the participant to run or walk 10 meters (on a straight walkway) from a standing position. Data are presented for change from baseline to Week 52 in the time (in seconds) taken to complete the 10MWR.

Time frame:
Baseline, Week 52 (Part 1)
Reported as:
Least squares mean · Seconds
Part 1: Change From Baseline in Time to Complete 10 Meter Walk/Run (10MWR) at Week 52
SecondsDelandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene Moxeparvovec
Part 1: Change From Baseline in Time to Complete 10 Meter Walk/Run (10MWR) at Week 52-0.34 ± 0.100.08 ± 0.10
Statistical analysis
  • Delandistrogene Moxeparvovec Followed by Placebo vs Placebo Followed by Delandistrogene Moxeparvovec · Mixed model of repeated measures · p = 0.0048 · Least squares mean change difference: -0.42 · 95% CI -0.71 to -0.13
SecondaryPart 1: Change From Baseline in Time to Complete 100 Meter Walk/Run (100MWR) at Week 52

The timed 100MWR quantifies the time required for the participant to run or walk 100 meters (on a straight walkway) from a standing position. Data are presented for change from baseline to Week 52 in the time (in seconds) taken to complete the 100MWR.

Time frame:
Baseline, Week 52 (Part 1)
Reported as:
Least squares mean · Seconds
Part 1: Change From Baseline in Time to Complete 100 Meter Walk/Run (100MWR) at Week 52
SecondsDelandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene Moxeparvovec
Part 1: Change From Baseline in Time to Complete 100 Meter Walk/Run (100MWR) at Week 52-6.57 ± 1.76-3.28 ± 1.80
Statistical analysis
  • Delandistrogene Moxeparvovec Followed by Placebo vs Placebo Followed by Delandistrogene Moxeparvovec · Mixed model of repeated measures · p = 0.1942 · Least squares mean change difference: -3.29 · 95% CI -8.28 to 1.70
SecondaryPart 1: Change From Baseline in the Timed Stair Ascend 4 Steps Test at Week 52

The timed stair ascend 4 steps test quantifies the time required for the participant to ascend 4 standard steps (each step was 6 inches in height). Data presented is the change from baseline to Week 52 in the time (in seconds) to ascend 4 steps.

Time frame:
Baseline, Week 52 (Part 1)
Reported as:
Least squares mean · Seconds
Part 1: Change From Baseline in the Timed Stair Ascend 4 Steps Test at Week 52
SecondsDelandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene Moxeparvovec
Part 1: Change From Baseline in the Timed Stair Ascend 4 Steps Test at Week 52-0.44 ± 0.12-0.08 ± 0.13
Statistical analysis
  • Delandistrogene Moxeparvovec Followed by Placebo vs Placebo Followed by Delandistrogene Moxeparvovec · Mixed model of repeated measures · p = 0.0412 · Least squares mean change difference: -0.36 · 95% CI -0.71 to -0.01
SecondaryPart 1: Change From Baseline in Stride Velocity 95th Centile (SV95C) at Week 52

Each participant was provided with wearable devices to collect data on stride velocity. Participants wore a device on each ankle. SV95C data was derived based on stride velocity. Data are presented for change from baseline to Week 52 in SV95C.

Time frame:
Baseline, Week 52 (Part 1)
Reported as:
Least squares mean · meters (m)/second (s)
Part 1: Change From Baseline in Stride Velocity 95th Centile (SV95C) at Week 52
meters (m)/second (s)Delandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene Moxeparvovec
Part 1: Change From Baseline in Stride Velocity 95th Centile (SV95C) at Week 520.06 ± 0.03-0.03 ± 0.03
Statistical analysis
  • Delandistrogene Moxeparvovec Followed by Placebo vs Placebo Followed by Delandistrogene Moxeparvovec · Mixed model of repeated measures · p = 0.0402 · Least squares mean change difference: 0.10 · 95% CI 0.00 to 0.19
SecondaryPart 1: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Score in Mobility to Week 52

PROMIS is a family of instruments developed and validated to assess health-related quality of life, including mobility. Mobility function scores ranged from 1 (worst mobility function) to 5 (best mobility function), where higher scores indicate a better clinical outcome.

Time frame:
Baseline, Week 52 (Part 1)
Reported as:
Least squares mean · Scores on a scale
Part 1: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Score in Mobility to Week 52
Scores on a scaleDelandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene Moxeparvovec
Part 1: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Score in Mobility to Week 520.05 ± 0.05-0.01 ± 0.05
Statistical analysis
  • Delandistrogene Moxeparvovec Followed by Placebo vs Placebo Followed by Delandistrogene Moxeparvovec · Mixed model of repeated measures · p = 0.4272 · Least squares mean change difference: 0.05 · 95% CI -0.08 to 0.19
SecondaryPart 1: Change From Baseline in PROMIS Score in Upper Extremity Function to Week 52

PROMIS is a family of instruments developed and validated to assess health-related quality of life, including upper extremity function. Upper extremity function scores ranged from 1 (not able to do so \[worst upper extremity function\]) to 5 (no trouble \[best upper extremity function\]), where higher scores indicate a better clinical outcome.

Time frame:
Baseline, Week 52 (Part 1)
Reported as:
Least squares mean · scores on a scale
Part 1: Change From Baseline in PROMIS Score in Upper Extremity Function to Week 52
scores on a scaleDelandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene Moxeparvovec
Part 1: Change From Baseline in PROMIS Score in Upper Extremity Function to Week 520.19 ± 0.070.23 ± 0.07
Statistical analysis
  • Delandistrogene Moxeparvovec Followed by Placebo vs Placebo Followed by Delandistrogene Moxeparvovec · Mixed model of repeated measures · p = 0.7324 · Least squares mean change difference: -0.04 · 95% CI -0.24 to 0.17
SecondaryPart 1: Number of Skills Gained or Improved at Week 52 as Measured by the NSAA

The NSAA is a clinician-administered scale that rates performance on various functional activities. As measured by the NSAA, data was collected for the number of skills gained (the average item score was 0 at Baseline and \> 0 at Part 1 Week 52) or improved (the average item score at Baseline was \> 0 but less than the average item score at Part 1 Week 52). As pre-specified, data are presented for the combined number of skills gained or improved at Week 52.

Time frame:
Week 52 (Part 1)
Reported as:
Least squares mean · number of skills
Part 1: Number of Skills Gained or Improved at Week 52 as Measured by the NSAA
number of skillsDelandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene Moxeparvovec
Part 1: Number of Skills Gained or Improved at Week 52 as Measured by the NSAA4.18 ± 0.313.99 ± 0.31
Statistical analysis
  • Delandistrogene Moxeparvovec Followed by Placebo vs Placebo Followed by Delandistrogene Moxeparvovec · Mixed model of repeated measures · p = 0.6554 · Least squares mean change difference: 0.19 · 95% CI -0.67 to 1.06
SecondaryParts 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

TEAEs were defined as an adverse event (AE) that emerged during treatment, having been absent pre-treatment, or worsened relative to the pretreatment state. SAEs were defined as any adverse event that resulted in death, was life threatening, required or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or was an important medical event. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to 104 weeks
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPart 1: Delandistrogene Moxeparvovec in Part 1 Followed by Placebo in Part 2Part 1: Placebo in Part 1 Followed by Delandistrogene Moxeparvovec in Part 2Part 2: Delandistrogene Moxeparvovec in Part 1 Followed by Placebo in Part 2Part 2: Placebo in Part 1 Followed by Delandistrogene Moxeparvovec in Part 2
TEAEs62575356
SAEs14558
SecondaryParts 1 and 2: Number of Participants With Adverse Events of Special Interest (AESI)

AESIs were defined as adverse events (AEs) of special interest, based on pre-specified criteria and pertain to categories labeled hepatotoxicity, immune-mediated myositis, thrombotic microangiopathy (TMA), hypersensitivity, thrombocytopenia, rhabdomyolysis, and troponin I elevations. The data represent the number of participants who experienced an event within the specified AESI category as observed by the principal investigator (PI), after adjudication. Per prespecified analysis, AESI data were only collected based on the specified AESI categories. A Summary of all SAEs and nonserious AEs ("Other"), regardless of causality and regardless of the AESI category, is located in the "Reported Adverse Events" section.

Time frame:
Up to 104 weeks
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Adverse Events of Special Interest (AESI)
ParticipantsPart 1: Delandistrogene Moxeparvovec in Part 1 Followed by Placebo in Part 2Part 1: Placebo in Part 1 Followed by Delandistrogene Moxeparvovec in Part 2Part 2: Delandistrogene Moxeparvovec in Part 1 Followed by Placebo in Part 2Part 2: Placebo in Part 1 Followed by Delandistrogene Moxeparvovec in Part 2
Hepatotoxicity120014
Immune-mediated Myositis0000
TMA0000
Hypersensitivity1010
Thrombocytopenia2010
Rhabdomyolysis1100
Troponin I elevations21148

Adverse events

Collected over Up to approximately 104 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Delandistrogene Moxeparvovec0/63 (0%)14/63 (22.2%)62/63 (98.4%)
Part 1: Placebo0/62 (0%)5/62 (8.1%)57/62 (91.9%)
Part 2: Placebo0/63 (0%)5/63 (7.9%)52/63 (82.5%)
Part 2: Delandistrogene Moxeparvovec0/60 (0%)8/60 (13.3%)55/60 (91.7%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPart 1: Delandistrogene MoxeparvovecPart 1: PlaceboPart 2: PlaceboPart 2: Delandistrogene Moxeparvovec
VomitingGastrointestinal disorders2/631/620/632/60
HepatotoxicityHepatobiliary disorders1/630/620/632/60
PyrexiaGeneral disorders1/631/620/632/60
COVID-19Infections and infestations2/631/620/630/60
Gamma-glutamyltransferase increasedInvestigations1/630/620/631/60
Hepatic enzyme increasedInvestigations1/630/620/631/60
Liver injuryHepatobiliary disorders1/630/620/631/60
GastroenteritisInfections and infestations0/630/620/631/60
Anal abscessInfections and infestations0/631/620/630/60
InfluenzaInfections and infestations0/631/620/630/60
Most frequent other events
Showing 10 of 54
Most frequent other events
EventPart 1: Delandistrogene MoxeparvovecPart 1: PlaceboPart 2: PlaceboPart 2: Delandistrogene Moxeparvovec
VomitingGastrointestinal disorders39/6311/629/6343/60
NauseaGastrointestinal disorders24/638/625/6323/60
CoughRespiratory, thoracic and mediastinal disorders12/6319/6212/6320/60
Decreased appetiteMetabolism and nutrition disorders20/633/621/6315/60
PyrexiaGeneral disorders19/6314/625/6312/60
Glutamate dehydrogenase increasedInvestigations18/632/621/6312/60
Upper respiratory tract infectionInfections and infestations13/6317/6210/6313/60
COVID-19Infections and infestations15/6310/626/636/60
DiarrhoeaGastrointestinal disorders6/6313/620/638/60
Gamma-glutamyltransferase increasedInvestigations5/630/622/6312/60

Baseline characteristics

Measured in the Modified Intent-to-Treat (mITT) Population, which included all randomized participants who received study treatment, with treatment group designated according to randomization.

Age, Continuous
Age, Continuous(years)Delandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene MoxeparvovecTotal
Mean5.98 ± 1.066.08 ± 1.056.03 ± 1.05
Sex: Female, Male
Sex: Female, Male(Participants)Delandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene MoxeparvovecTotal
Female000
Male6362125
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Delandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene MoxeparvovecTotal
Hispanic or Latino15823
Not Hispanic or Latino4753100
Unknown or Not Reported112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Delandistrogene Moxeparvovec Followed by PlaceboPlacebo Followed by Delandistrogene MoxeparvovecTotal
American Indian or Alaska Native000
Asian81119
Native Hawaiian or Other Pacific Islander000
Black of African American022
White494695
More than One Race101
Other or Not Reported538
08

Study locations

42 sites
  • Arkansas Children's
    Little Rock, Arkansas 72202, United States
  • UC San Diego Altman Clinical and Translational Research Institute
    La Jolla, California 92037, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Lucile Packard Children's Hospital at Stanford
    Palo Alto, California 94304, United States
  • University of California, Davis
    Sacramento, California 95817, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • University of Florida
    Gainesville, Florida 32608, United States
  • Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Iowa Stead Family Children's Hospital
    Iowa City, Iowa 52242, United States
  • The Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Washington University of St. Louis
    St Louis, Missouri 63110, United States
  • Columbia University/NYPH
    New York, New York 10032, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Duke University Medical Center, Lenox Baker Children's Hospital
    Durham, North Carolina 27705, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43210, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84132, United States
  • Children's Hospital of the King's Daughters
    Norfolk, Virginia 23510, United States
  • Children's Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • University Hospital Ghent
    Ghent, 9000, Belgium
  • LMU - Klinikum der Universitaet Muenchen - Kinderklinik und
    Bayern, 80337, Germany
  • Universitätsklinikum Essen - Klinik für Kinderheilkunde I
    Essen, 45147, Germany
  • University Hospital Hamburg- Eppendorf
    Hamburg, 20251, Germany
  • Hong Kong Children's Hospital
    Kowloon, Hong Kong
  • IRCCS Istituto G.Gaslini, U.O.
    Genoa, 16147, Italy
  • UOC Neurologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • UOC Neuropsichiatria Infantile, Area Salute del Bambino, Fondazione Policlinico Universitario A. Gamelli IRCCS
    Roma, 00168, Italy
  • Kobe University Hospital
    Kobe, 650-0017, Japan
  • National Center for Child Health and Development
    Tokyo, 157-8535, Japan
  • Tokyo Women's Medical University Hospital - Pediatrics
    Tokyo, 162-8666, Japan
  • National Center of Neurology and Psychiatry
    Tokyo, 187-8551, Japan
  • Hospital Universitari i Politécnico La Fe
    Valencia, Comunidad Valencia, Spain
  • Hospital Sant Joan de Déu
    Barcelona, 08950, Spain
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, 807, Taiwan
  • National Taiwan University Hospital
    Taipei, 100225, Taiwan
  • Oxford University Hospitals NHS Foundation Trust
    Headington, Oxford OX3 9DU, United Kingdom
  • Great Ormond Street Hospital for Children NHS Foundation Trust
    London, WC1N3JK, United Kingdom
  • The Newcastle Upon Tyne NHS Hospital NHS Foundation Trust, Royal Victoria Infirmary
    Newcastle upon Tyne, NE1 4LP, United Kingdom
09

References and documents

Publications

  • Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, Leon-Astudillo C, Nascimento A, Proud C, Schara-Schmidt U, Veerapandiyan A, Zaidman CM, Guridi M, Murphy AP, Reid C, Wandel C, Asher DR, Darton E, Mason S, Potter RA, Singh T, Zhang W, Fontoura P, Elkins JS, Rodino-Klapac LR. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025 Jan;31(1):332-341. doi: 10.1038/s41591-024-03304-z. Epub 2024 Oct 9. PubMed 39385046 ↗
  • Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, Leon-Astudillo C, Nascimento A, Proud C, Schara-Schmidt U, Veerapandiyan A, Zaidman CM, Furgerson M, Ding K, Singh P, Potter R, Asher DR, Murphy AP, Reid C, Hooper G, Torre CO, Manfrini M, Rodino-Klapac LR. Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial. Neurol Ther. 2026 Apr;15(2):545-559. doi: 10.1007/s40120-025-00879-8. Epub 2026 Jan 10. PubMed 41518520 ↗
  • Audhya I, Nacson AB, Gooch K, Basnyat B, Slota C, Martin S, Murphy A, Lansdall CJ, Ciobanu T, Nascimento A, Veerapandiyan A. Caregiver-reported Patient Experiences with Duchenne Muscular Dystrophy: Qualitative In-trial Interviews 1 Year After Delandistrogene Moxeparvovec in the Pivotal EMBARK Trial. Neurol Ther. 2026 Feb;15(1):41-60. doi: 10.1007/s40120-025-00842-7. Epub 2025 Nov 3. PubMed 41182527 ↗
  • Vandenborne K, Walter GA, Straub V, Willcocks RJ, Forbes SC, Mercuri EM, Muntoni F, Ding K, Ennamuri S, Reid C, Murphy AP, Manfrini M, Mendell JR, Elkins JS, Rodino-Klapac LR. Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical Trial. JAMA Neurol. 2025 Jul 1;82(7):734-744. doi: 10.1001/jamaneurol.2025.0992. PubMed 40354061 ↗
  • McDonald CM, Elkins JS, Dharmarajan S, Gooch K, Ciobanu T, Lansdall CJ, Murphy AP, McDougall F, Mercuri EM, Audhya I; EMBARK Study Group. Caregiver Global Impression Observations from EMBARK: A Phase 3 Study Evaluating Delandistrogene Moxeparvovec in Ambulatory Patients with Duchenne Muscular Dystrophy. Neurol Ther. 2025 Feb;14(1):211-225. doi: 10.1007/s40120-024-00685-8. Epub 2024 Nov 26. PubMed 39589719 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Oct 2023, 23 months.

Results were first posted in Dec 2024, 1 year 2 months after primary completion.

Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2021
First posted
Oct 27, 2021
StartActual
Oct 27, 2021
Primary completionActual
Oct 4, 2023
CompletionActual
Oct 25, 2024
Results first posted
Dec 10, 2024
Last update
Jul 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05096221
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 27, 2021
Start date
Oct 27, 2021
Primary completion
Oct 4, 2023
Completion
Oct 25, 2024
Results posted
Dec 10, 2024
Last update
Jul 8, 2025

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion